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Abstract 
Introduction: A large body of evidence supports the inflammatory hypothesis of 
atherosclerosis. And both innate and adaptive immune responses play important 
roles in all disease stages.  
Areas covered: Here, we review our understanding of the role of the immune 
response in atherosclerosis, focusing on the pathways currently amenable to 
therapeutic modulation. We also discuss the advantages or undesirable effects that 
may be foreseen from targeting the immune response in patients at high 
cardiovascular risk, suggesting new avenues for research. 
Expert commentary: There is an extraordinary opportunity to directly test the 
inflammatory hypothesis of atherosclerosis in the clinic using currently available 
therapeutics. However, a more balanced interpretation of the experimental and 
translational data is needed, which may help address and identify in more detail 
the appropriate settings where an immune pathway can be targeted with minimal 
risk. 
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Abbreviations 
 
Cardiovascular (CV) 
Low-density lipoproteins (LDL) 
Pathogen associated molecular patterns (PAMPs) 
Damage-associated molecular patterns (DAMPs) 
Pattern recognition receptors (PRR) 
Dendritic cells (DC) 
Immunoglobulins (Ig) 
T cell receptors (TCR) 
Oxidized-LDL (oxLDL) 
High-sensitivity C-reactive protein (hsCRP) 
Endothelial cells (EC) 
Smooth muscle cells (SMC) 
IL1-receptor type-I (IL1R1) 
Mitochondrial uncoupling protein (UCP) 
IL1R accessory protein (IL1RAP) 
myeloid differentiation factor 88 (MyD88) 
c-Jun N terminal kinases (JNKs) 
Extracellular signal-regulated kinases (ERKs) 
Mitogen-activated protein kinases (MAPKs) 
IL1R antagonist (IL1Ra) 
Macrophage colony-stimulating factor (M-CSF) 
Bone marrow transplantation (BMT) 
Acute coronary syndromes (ACS) 
Coronary artery disease (CAD) 
Oxidized phospholipids (OxPL) 
Rheumatoid arthritis (RA) 
Subcutaneous (s.c.) 
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) 
Methotrexate (MTX) 
5-aminoimidazole-4carboxamide ribonucleotide (AICAR) 
lectin-like oxidised LDL receptor -1 (LOX1) 
Cardiovascular Inflammation Reduction Trial (CIRT) 
Acute phase response (APR) 
Suppressor of cytokine signaling 3 (SOCS3) 
Lipoprotein a (Lp(a)) 
Platelet-activator factor factor (PAF) 
Lysophosphatidylcholine (LysoPC) 
Stabilization of Atherosclerosis Plaque by Darapladib Initiation of Therapy 
(STABILITY) 
 Stabilization of Plaques Using Darapladib-Thrombolysis in MI 52 Trial (SOLID-
TIMI 52) 
Fewer Recurrent Acute coronary events with Near-term Cardiovascular 
Inflammation Suppression (FRANCIS)  
Antigen presenting cells (APC) 
Major histocompatibility complex class II molecule (MHCII) 
T regulatory (Tregs) 
Retinoic acid orphan receptors (ROR) 
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Naturally occurring Tregs (nTregs) 
Adaptive/induced Treg cells (iTreg) 
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Introduction 
 
Atherosclerosis is responsible for most ischemic cardiovascular (CV) diseases and 
is a leading cause of death and morbidity worldwide. Atherosclerosis is a complex 
arterial pathology with multiple genetic and environmental risk factors, initiated in 
response to trapping of low-density lipoproteins (LDL) in the intima and their 
acquisition of immunogenic properties through both enzymatic and non-enzymatic 
(oxidative) modifications. The subsequent immune response involves interactions 
between many vascular and circulating cells and mediators, and frequently leads 
to a chronic inflammatory state due at least in part to defects in counter-regulatory 
mechanisms. Broad evidence supports the inflammatory theory of atherosclerosis, 
and immune cells have been shown to participate in all stages of the disease from 
its initiation to progression and plaque rupture or erosion. 
An innate immune response is initiated by the recognition of signature molecules 
that the organism considers as carrying a danger. Those molecules can be of 
microbial origin (i.e. pathogen associated molecular patterns or PAMPs) or self-
molecules that are only secreted or exposed to the immune system in case of cell 
injury or death (i.e. damage-associated molecular patterns or DAMPs). Following 
recognition through germline encoded receptors (called pattern recognition 
receptors PRR) expressed in innate immune cells (e.g., monocytes/macrophages, 
neutrophils, dendritic cells (DC), NK cells, B1 cells), PAMPs and DAMPs activate 
protective responses leading to the killing of the microbe or the clean-up and 
repair of dead tissue.  
The adaptive immune response is induced by other types of molecules (i.e. 
antigens), which are recognized by highly selected, clonally developed and specific 
antigen receptors, e.g., immunoglobulins (Ig) in B cells, and T cell receptors (TCR) 
in T cells. Antigen recognition in combination with additional signals delivered by 
co-stimulatory molecules and soluble mediators, lead to the proliferation and 
differentiation of lymphocytes into antigen-specific effector cells helping to 
eradicate the aggression. 
When the stimuli are persistent (as it may be the case for oxidized-LDL (oxLDL) or 
cholesterol crystals in atherosclerosis), continued innate and adaptive immune 
activation will promote chronic inflammation, damaging the tissues and leading to 
disease. Patients with elevated inflammatory biomarkers such as high-sensitivity 
C-reactive protein (hsCRP) have increased CV risk, and recent work directly 
implicates both the innate and adaptive immune pathways in the development and 
complications of human atherosclerosis. Yet, it remains unknown whether 
targeted inhibition of immune responses will reduce CV event rates. In the present 
review we will discuss the role of selective innate and adaptive immune responses 
in atherosclerosis. We will focus on currently targeted pathways, and pathways 
that are susceptible to be targeted by available drugs; we will explain how this 
basic and experimental knowledge may be translated to the clinic with the aim to 
develop better therapies and reduce disease burden. 
 
Therapies targeting the innate immune response  
 
IL1 pathway  
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Pathophysiological pathway: The IL1 family of cytokines comprises 11 proteins, 
encoded by different genes, which initiate and regulate inflammatory processes 
[1]. The founding members are IL1 and IL1, which exert the most potent pro-
inflammatory effects. They are mainly produced by monocytes and macrophages 
but also in lower amounts by neutrophils, keratinocytes, epithelial and endothelial 
cells (EC), lymphocytes, smooth muscle cells (SMC) and fibroblasts. Despite IL1 
and IL1 only showing a 24% amino acid sequence homology, they display largely 
identical biological functions. They both bound to the same surface receptor, called 
IL1-receptor type-I (IL1R1), which is ubiquitously expressed. 
 IL1 is synthesized as a 33kDa precursor peptide (proIL1) that can be cleaved 
by the activation of the calcium-dependent membrane-associated cysteine 
protease calpain to produce an active 17kDa peptide with full biological activity 
[2].  IL1 activation depends on the cell type and IL1 is up to 50 fold times more 
active than proIL1 due to increased IL1R1 affinity for IL1 [3]. In some cells, 
there is also an IL1R2 that binds to proIL1 impairing calpain-mediated cleavage. 
However, following inflammasome activation, caspase-1 specifically cleaves IL1R2 
and restores full IL1 activity [3]. An inflammasome-independent mechanism of 
IL1 production was also described recently.  Fatty acids selectively stimulated the 
release of IL1 in macrophages by a mechanism involving the mitochondrial 
uncoupling protein (UCP)2 [4]. Interestingly, UCP2 in turn may promote 
inflammasome-dependent caspase-1 activation and IL1 production through 
modulation of de novo fatty acid synthesis [5].  
 IL1 is synthesized as a biologically inactive 31kDa precursor peptide (proIL1) 
(extensively reviewed in [6]). Pro-IL1 must be cleaved, mainly by caspase-1, to 
generate an active 17kDa peptide and to exert its function. Caspase-1 is regulated 
by a multiprotein oligomer, known as inflammasome, which acts as a sensor of the 
innate immune response. Activation of NLRP3 inflammasome can be induced by 
particulate ligands (i.e. cholesterol crystals in atherosclerosis)  [7] or soluble 
ligands (i.e.  oxidized LDL) converted intracellularly into crystals [8]. 
 IL1 and/or  binding to IL1R1 induces the recruitment of a second receptor 
chain called IL1R accessory protein (IL1RAP) to the intracellular domain of IL1R1. 
The IL1( or )-IL1R1-IL1RAP ternary complex recruits several intracellular 
adaptor proteins to trigger a signaling cascade that activates pro-inflammatory 
transcription factors (reviewed in [1]). As a result, IL1 signaling leads to the 
activation of several target genes like pro-inflammatory molecules (e.g.. TNF, IL6, 
IL8, etc.), EC adhesion molecules, and macrophage colony-stimulating factor 
(CSF1), etc. 
IL1R antagonist (IL1RN) is a major natural competitive inhibitor of the binding of 
IL1 to its receptor. Despite the same affinity of IL1 and IL1RN for IL1R1, there is a 
need for a large molar excess of IL1RN (100 to 1000-fold) to block IL1 activity 
IL1R antagonist (IL1RN) is a major natural competitive inhibitor of the binding of 
IL1 to its receptor. Despite the same affinity of IL1 and IL1RN for IL1R1, there is a 
need for a large molar excess of IL1RN (100 to 1000-fold) to block IL1 activity [6]. 
Experimental evidence: A role for IL1 has been described in both early [9–11] 
and advanced [12,13] atherosclerosis. At the early stages of fatty streaks 
formation, exogenous administration [9] of IL1RN or its genetic overexpression 
[10,11] decreases atherosclerotic plaque formation in murine models. Apoe-/- mice 
lacking IL1RN develop a severe form of aortic inflammation with massive 
macrophage infiltration in the adventitia, macrophage lipid accumulation, and 
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marked destruction of the aortic lamina [11]. This effect is not observed in Il1rn-/- 
mice on Apoe+/+ background, suggesting that the lack of IL1RN is not sufficient to 
promote arteritis in normo-cholesterolemic animals. 
In contrast, the role of IL1 signaling in more advanced stages of atherosclerosis 
remains debated. For example, plaque size did not differ between Apoe-/-/IL1r1+/+ 
and Apoe-/-/Il1r1-/- mice but the latter developed more unstable-appearing 
plaques, as revealed by reduced collagen and SMC accumulation and increased 
occurrence of intraplaque haemorrhage [12]. Thus, animal models of 
atherosclerosis have shown a dual role for IL1, pro-atherogenic at early stages, but 
potentially protective (enhancing plaque stability) at advanced stages. IL1R1 and 
IL1RN respectively mediate and inhibit both IL1 and IL1, but whether the 2 
forms of IL1 exhibit similar or contrasting roles in atherosclerosis is still under 
intense investigation. 
C57Bl6 Il1b-/- mice showed decreased atherosclerotic plaques after high fat diet. 
The same atheroprotective effect was observed in Il1a-/- despite increased non-
HDL-cholesterol levels. Bone marrow transplantation (BMT) from Il1a-/- mice into 
WT mice did not alter lipoprotein levels but still decreased atherosclerotic plaque 
formation. However, BMT from Il1b-/- did not affect plaque size [14]. Thus only 
IL1 secretion from bone marrow-derived cells appears to be atherogenic. This 
conclusion is supported by recent data obtained in Ldlr-/- mice [4]. Nevertheless, 
treatment with monoclonal antibodies against IL1 (XOMA 052) in atherosclerotic 
mice, significantly decreased atherosclerotic plaque formation associated with 
reduced non-HDL/HDL ratio, plaque lipid content and macrophage infiltration 
[15].  
Translational studies: In the late 80´s several in vitro experiments using human 
cell cultures suggested a potential role of IL1 in atherosclerosis. In vitro IL1 
regulates SMC mitogenesis [16], induces leukocyte adhesion to the endothelium 
[17], modulates LDL oxidation [18], and promotes vascular permeability [19]. Both 
IL1 and IL1 were detected in human atherosclerotic plaques [20], IL1 being 
mostly released by macrophages and active IL1 by SMC [21,22].  
IL1 is almost undetectable in blood using routine methods, so only a very few 
epidemiological studies are available on the relationship between circulating IL1 
and CV risk [23]. Patients with greater atherosclerotic burden [24,25] presented 
increased IL1 levels, which were associated with less favorable prognosis after 
acute coronary syndromes (ACS) [26,27]. 
Two polymorphisms have been described for the IL1B gene, the frequent variant 
IL1B*1 (a single transition from C-T in position -511) and the rare variant IL1B*2 
(a single transition C-T in exon 5 in position +3953). Only one study found an 
association between specific combinations of these polymorphisms and the risk of 
developing coronary artery disease (CAD) in individuals with increased oxidized 
phospholipids (OxPL)/apoB ratio [28]. The polymorphic region within intron 2 of 
the IL1 receptor antagonist gene (IL1RN) contains a variable number of tandem 
repeats of 86 base pairs, with IL1RN*1 representing four repeats of the 86 bp in 
tandem, IL1RN*2 having two repeats, and IL1RN*3 containing five repeats [29]. 
Carriers of the IL1RN*2 polymorphism release more IL1RN, which was related to 
reduced atherosclerotic plaque size in some European populations [30,31], but not 
in others [32]. Recently, another two uncorrelated variants rs6743376 and 
rs1542176 located upstream of IL1RN were identified as the strongest known 
genetic determinants of circulating IL1RN concentrations. The authors developed a 
 7 
genetic score combining the alleles of those two common variants and compared it 
with the effects of anakinra (recombinant IL1RN) on inflammatory biomarkers in 
rheumatoid arthritis (RA), diabetes mellitus type 2, coronary heart disease, stroke 
and aortic aneurysm in a total of 453411 participants.  For each IL1RN minor allele 
inherited, there was a significant decrease of IL6 and hsCRP that correlated with 
the effect of anakinra. Interestingly, individuals with increased number of 
inherited minor alleles (corresponding to higher IL1RN levels) showed decreased 
risk of RA but, surprisingly, increased CV risk (CAD, ischemic stroke and abdominal 
aortic aneurysm) [33]. IL1RN minor alleles were also associated with a significant 
increase of circulating lipoproteins like LDL-cholesterol. However, the latter only 
explained 33% of the increase in CV risk associated with IL1RN genotype. Thus, 
similarly to experimental data, translational human data remain inconclusive 
regarding the direct role of IL1 the pathogenesis and complications of CV diseases. 
Clinical trials: During the last 15 years several molecules have been used to 
modulate IL1 pathway in autoimmune and chronic inflammatory diseases. 
Anakinra was the first selective inhibitor of IL1 pathway approved by the FDA to 
treat several autoinflammatory diseases like RA [34] and it is now undergoing 
clinical trials to treat other immune-mediated diseases. The effect of anakinra in 
CV disease was tested in a Phase II, multi-center, placebo-controlled trial, 
comparing the administration of a subcutaneous (s.c.) daily injection of anakinra 
(100 mg) for 14 consecutive days in non-ST elevation ACS patients. Anakinra 
significantly decreased CRP levels compared to placebo during the treatment 
period. However, a rebound of CRP was observed after treatment discontinuation 
in the anakinra group. Furthermore, major adverse cardiac events were 
significantly increased in the anakinra group after 1 year of follow-up [35]. 
Another important limitation of anakinra is its short-half life requiring frequent 
injections or high doses, which may be very inconvenient for the patient. 
Owing to its specificity and long half-life, antibody-based neutralization of IL1 is 
emerging as a more attractive therapeutic strategy. Canakinumab, is a specific IL1 
neutralizing monoclonal antibody that has recently been approved by the FDA for 
the treatment of several auto-inflammatory diseases (i.e. cryoporin-associated 
periodic syndromes). It is being tested in the Canakinumab Anti-Inflammatory 
Thrombosis Outcomes Study (CANTOS), which is currently testing the impact of 
IL1β inhibition as compared to placebo on recurrent CV events (MI, stroke, and CV 
death). Stable post-myocardial infarction (MI) CAD patients who remained at high 
CV risk as revealed by persistent elevations of CRP (>2 mg/L) despite 
contemporary secondary prevention strategies have undergone random 
assignment to s.c. canakinumab 50 mg, 150 mg or 300 mg or placebo every 3 
months (in addition to standard pharmacological treatment). This trial is 
conducted in more than 40 countries worldwide in 146 centers and will recruit 
17,400 patients [36]. Pilot data are available from 556 men and women who were 
randomly allocated to s.c. placebo or canakinumab (5, 15, 50 or 150 mg monthly) 
and followed up for 4 months. There were dose-dependent and significant 
decreases of hsCRP, IL6 and fibrinogen levels in canakinumab-treated patients 
compared to placebo [37]. However, there was also a modest but significant 
increase in circulating triglycerides levels related to the high doses of 
canakinumab, which might offset, at least in part, the favorable anti-inflammatory 
profile. The effect of canakinumab on major CV events will be reported in 2017. 
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Colchicine, a natural component originally extracted from plants (genus 
Colchicum) that has been used to treat gout for centuries, is now also being 
considered for the treatment of atherosclerotic disease. Gout is an inflammatory 
disease characterized by the deposit of sodium urate crystals that act as DAMPs 
and activate the inflammasome/IL1 pathway. Colchicine inhibits inflammasome 
activation in neutrophils as it forms a tubulin-colchicine complex that prevents the 
formation of microtubules [38]. Microtubules are necessary for the transport of 
NLRP3 to the mitochondria for correct assembly of the inflammasome. Since 
cholesterol crystals activate the inflammasome pathway in a manner very similar 
to urate crystals, colchicine is now considered as potentially useful in treating CAD 
and acute CV events. Short-term administration of colchicine significantly limits 
local (heart circulation) but not systemic production of IL1, IL6 and IL18 in ACS 
patients, suggesting a selective anti-inflammatory effect [39,40]. The low dose 
colchicine (Lo-Do-Co) clinical trial was a prospective, randomized, observer-
blinded endpoint design in 532 patients with stable CAD who randomly received a 
low dose of colchicine (0.5 mg/day) or placebo (besides standard pharmacological 
treatment) for 3 years. The addition of colchicine to these patients significantly 
reduced the risk of fatal CV event [41]. A recent meta-analysis of colchicine trials, 
including those in pericarditis, points towards an overall benefit on CV risk 
reduction [42]. However, it should be acknowledged that data interpretation or 
validity may be significantly limited by the lack of blinding, lack of placebo control, 
and a high rate of dropouts in patients assigned to colchicine. 
 
Methotrexate 
Pathophysiological pathway: Methotrexate (MTX) is an antimetabolite approved 
by the FDA for use in some neoplastic diseases, severe psoriasis and adult RA. MTX 
was originally designed as an antagonist for folic acid. At high doses (used for 
several cancers), it blocks dihydrofolic acid reductase impairing purines and 
pyrimidines synthesis and thereby DNA synthesis and replication of tumor cells.  
In 1951, MTX was first introduced to treat RA based on the rationale that it should 
inhibit proliferation of leukocytes and other cells that accumulate in the inflamed 
joints [43]. Low doses of MTX have an anti-inflammatory effect, based on the 
clinical observation that they decrease the levels of pro-inflammatory mediators, 
but the precise anti-inflammatory mechanism is still unresolved. Several 
hypotheses may tie together to explain the anti-inflammatory effect of MTX: 
1. Folate antagonistic action, whereby MTX may inhibit T cell proliferation at 
sites of joint inflammation in RA [44]. However, administration of folic and folinic 
acid does not decrease its anti-inflammatory effect [45]. 
2. Inhibition of potentially toxic transmethylation compounds leading to a 
decrease of polyamines. Despite polyamines having some anti-oxidative 
properties, their excessive accumulation and subsequent catabolism may increase 
the generation of toxic NH3 and H2O2 [46]. MTX inhibits the synthesis of 
tetrahydrofolate that is necessary for the synthesis of methionine, S-adenosyl-
methionine and downstream polyamines. However, drugs used to inhibit the 
formation of these polyamines like 3-deazaadenosine did not exert any positive 
effect on RA, mainly because a correct cellular content of polyamines is necessary 
for their antioxidative functions. 
3. Increased concentrations of extracellular adenosine: MTX is metabolized in 
the liver to 7-hydroxy-MTX and converted into polyglutamated MTX. These 
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polyglutamates inhibit 5-aminoimidazole-4carboxamide ribonucleotide (AICAR) 
formilase leading to intracellular AICAR accumulation. AICAR accumulation leads 
to enhance release of adenine nucleotides and their extracellular conversion to 
adenosine. Adenosine exhibits several anti-oxidant and anti-inflammatory effects. 
AICAR may also activate AMPK to inhibit macrophage inflammatory responses 
[47]. 
Despite all these potential mechanisms of action, it is still unclear how MTX exerts 
its anti-inflammatory response.  
 
Experimental evidence: Evidence that MTX could be useful in the treatment of CV 
diseases derives from clinical trials in RA patients where MTX treatment was 
associated with a significant reduction of fatal CV events [48]. Paradoxically, very 
few experimental studies were launched to elucidate its direct role in CV disease. 
In one experimental study, MTX significantly decreased atherosclerotic plaque 
formation in rabbits fed a high cholesterol diet, and was associated with decreased 
macrophage migration and reduced apoptosis within the plaque [49]. In a murine 
model of inflammatory vasculopathy, administration of low dose MTX significantly 
reduced intramyocardial vasculopathy and attenuated end-organ damage. In that 
study, MTX up-regulated AMPK-CREB pathway in EC, activating a cytoprotective 
program [50]. 
In vitro experiments suggested that the atheroprotective role of MTX could also 
rely on enhanced reverse cholesterol transport and impairment of foam cell 
formation. Treatment of human blood monocyte-derived macrophages with MTX 
significantly increased adenosine, which activated 27-hydroxylase through A2A 
receptors. Increased generation of 27-hydroxycholesterol up-regulated ABCA1 
gene expression, possibly through LXR activation, thereby increasing reverse 
cholesterol transport [51]. The effect of MTX on inhibition of foam cell formation 
was also attributed to A2A receptor stimulation by adenosine presumably 
decreasing  lectin-like oxidised LDL receptor -1 (LOX1) expression [52].  
Translational studies: Current information on MTX and CV risk derives from 
observational studies and clinical trials in patients with RA, psoriasis or 
polyarthritis treated with MTX, in whom CV events were reported. Several meta-
analysis of those studies reached the same conclusion that MTX administration is 
associated with a significant decrease in CV events [48,53–56]. One of the largest 
cohort studies (n=16,752) detected a 35% decrease in CV morbidity in the group 
treated with MTX compared to non-MTX treated patients after a follow-up of 4 
years [57]. Another study that recruited a total of 6,707 veterans with RA on 
database (90% males and 10% females) compared the effect of low to high-dose of 
MTX on the incidence of CV morbidity. The study reported a 35% significant 
decrease in CV morbidity on low-dose MTX, while no effect on morbidity was 
found in the high dose treated group [58].  
Clinical trials: Based on those encouraging results and the relative security of 
MTX use in RA, it has been hypothesized that MTX could be beneficial to patients 
who do not present with RA but are at high risk of CV events. Additional 
advantages of MTX in the setting of CV disease include its safety profile at low 
doses and the fact that it does not affect lipoprotein metabolism in an unfavorable 
manner, as it is the case for some other anti-inflammatory drugs. The first trial, 
Cardiovascular Inflammation Reduction Trial (CIRT), has been funded by the 
NHLBI and is currently evaluating the effect of low-dose MTX (target dose, 15-20 
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mg/wk) as compared to placebo on the reduction of major vascular events. The 
trial will include 7,000 patients with prior MI who are already diagnosed either 
with diabetes type 2 or metabolic syndrome. The primary endpoint is a composite 
of non-fatal MI, stroke, and CV death [59]. The trial is expected to provide an 
interesting complementary therapeutic strategy for the secondary prevention of 
CV events. 
 
IL6 pathway 
Pathophysiological pathway: IL6 is a pleiotropic cytokine with a wide range of 
biological activities in inflammation and immune regulation. All members of the 
IL6 family bind to the signal transducer of cytokines related to IL6 called 
glycoprotein 130 (gp130) exerting pleiotropic effects (reviewed in[60]).  
IL6 binds the 80 kDa type I transmembrane glycoprotein termed membrane IL6 
receptor (mIL6R), and gp130. This complex IL6-mIL6R-gp130 activates the 
classical IL6 signal transduction pathway [61]. mIL6R is only expressed on the 
surface of some cell types like hepatocytes, neutrophils, and some types of 
macrophages and T cells; thus classical activation is restricted to those cells. IL6 
pathway activates JAK tyrosine kinases and promotes the recruitment and 
phosphorylation of STAT3 to induce downstream effector responses, for example, 
activation of the inflammatory acute phase response (APR) (i.e., CRP and 
fibrinogen production) in hepatocytes [62]. This is counterbalanced by the 
activation of the suppressor of cytokine signaling 3 (SOCS3), which binds to gp130 
inhibiting JAK activity [63]. Intriguingly however, in the absence of SOCS3, 
prolonged activation of STAT3 by IL6 switches downstream responses towards the 
activation of an anti-inflammatory program [64]. IL6 also activates IL4 receptor 
expression in macrophages, thus promoting their polarization into an anti-
inflammatory M2 phenotype [65]. Thus, depending on local cues, IL6 may exert 
both pro and anti-inflammatory effects.  
IL6 pathway is even more complicated due to the ubiquitous expression of gp130 
and the presence of a soluble IL6R, allowing trans-signaling even in the absence of 
the mIL6R [66]. There are two potential mechanisms that lead to the formation of 
sIL6R. The first one involves the proteolytic cleavage of the mIL6R and is 
dependent on metalloproteases of the ADAM family (specifically ADAM10 and 
ADAM17). The second one implies an alternative splicing mechanism of IL6R 
mRNA and has been described in humans but not in mice. Homodimers of gp130 
are unable to activate the IL6 cascade just through binding to IL6. However, they 
do so in the presence of sIL6R. IL6 trans-signaling is therefore very important for 
cells that do not express mIL6R at any stage of development or activation. Several 
mechanisms related to atherosclerosis, such as T cell trafficking and proliferation, 
or activation of EC and SMC, may be independent of mIL6R but regulated through 
IL6 trans-signaling [67].  
The glycoprotein gp130 is also present in a soluble form, mainly the result of 
alternative splicing [68]. Soluble gp130 can bind the IL6-sIL6R complex acting as a 
competitive inhibitor and impairing trans-signaling. 
Classical and trans-signaling would be expected to have the same effect upon IL6 
production. However, experimental results point to the activation of differential 
downstream responses depending on the cell type and the state of cell activation 
[69]. Thus, it is be very important to consider the specific contribution of classical 
 11 
and trans-activation to the development of a CV disease in order to propose 
specific and accurate therapeutic strategies. 
Experimental evidence: Experiments in mice performed to study the role of IL6 
in atherosclerosis have led to controversial and unexpected results. Exogenous and 
sometimes supra-physiological IL6 injections were reported to enhance 
atherosclerosis, in part due to increased oxLDL uptake by macrophages in Apoe-/- 
mice [70,71]. However, Apoe-/-/Il6-/- mice presented larger and more calcified 
atherosclerotic plaques compared to Il6+/+/Apoe-/- mice after the consumption of a 
normal chow diet for 1 year [72]. These results were also corroborated in C57Bl6 
Il6-/- mice fed a Paigen diet for 15 weeks, which exhibited larger fatty streak 
lesions than their WT littermates [73]. Ldlr-/-/Il6-/- developed atherosclerotic 
plaques that were comparable in size to those seen in their Ldlr-/- littermates, 
despite showing a significant decrease in acute phase reactants [74]. Thus, 
currently there is more experimental evidence that argues in favor of a protective 
rather than detrimental role of IL6R signaling in atherosclerosis. Studies 
performed with gp130 loss and gain of function models are also far from 
conclusive. Specific gp130 hepatic deletion in Apoe-/- mice significantly decreased 
APR reactants and atherosclerotic plaque formation. However, gp130 
overexpression in Apoe-/- was associated with reduced (or no change in) 
atherosclerotic plaque formation despite increased production of APR reactants 
and macrophage infiltration [75].  
On the other hand, the contribution of IL6-trans signaling to atherosclerosis has 
not been studied thoroughly. Based on the only experiment that has been reported 
so far, IL6 trans-signaling is considered as an important contributor to 
atherogenesis [76]. Ldlr-/- mice treated with recombinant sgp130-Fc (to selectively 
block IL6 trans-signaling) showed significant reduction in the development of 
atherosclerosis, which was attributed to a decrease of EC activation and SMC 
migration. Nevertheless, results from that experiment may be biased due to the 
fact that the control group was injected with saline and did not receive a human 
control IgG to match the experimental group that received sgp-130Fc of human 
origin. Thus, further validation experiments are needed to better elucidate the 
contribution of IL6 trans-signalling to atherosclerosis. 
Translational studies: IL6 is highly expressed in atherosclerotic plaques, but 
whether it exerts a pro- or anti-atherosclerotic role remains unclear, as both pro- 
and anti-inflammatory properties have been reported. For example, IL6 signaling 
pathway enhances vascular cell activation but also promotes SMC survival. It 
activates T cells and promotes their differentiation towards the Th17 subset, with 
either pro- or anti-atherogenic properties (see below). IL6 also promotes an anti-
inflammatory macrophage phenotype and may enhance the synthesis of IL1RN 
and the production of soluble TNF receptor.  
Epidemiological studies in general found a significant association between high 
IL6/sIL6R levels and CV risk [77–80] without providing any causal explanation.  
More recent Mendelian randomization studies tried to address the issue of 
casuality and focused on a SNP in the IL6R that was highly associated with 
increased circulating concentrations of IL6 and sIL6R [81,82] but reduced 
expression of mIL6R. Both studies found that the IL6R SNP rs2228145 (IL6R 
Asp158Ala) was not associated with lipid concentrations, blood pressure, 
adiposity, dysglycemia or smoking. Nevertheless, the 358Ala variant was 
associated with a significant decrease of CRP and fibrinogen levels, and reduced 
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risk of CV disease. The data was interpreted as a proof that reduced IL6 signaling 
was responsible for the reduced risk of CVD. It is intriguing to note however that 
others have linked the same polymorphism to increased risk of asthma and 
interpreted their results as a proof-of-concept that increased (not decreased) IL6 
signaling was responsible for the increased risk of asthma [83,84]. Thus, the same 
IL6R polymorphism is associated on one hand with increased risk of asthma, 
pushing investigators to propose IL6 blockade as a strategy to treat the disease, 
and on the other hand with reduced risk of CVD, leading investigators to support 
IL6 blockade as a promising strategy to reduce CVD risk. This testifies to our 
limited knowledge about the true impact of that polymorphism on IL6 signaling. 
Soluble Il6R is believed to act as an IL6 buffer system limiting IL6 signaling. 
However, as explained above, sIL6R binding to IL6 also activates IL6 trans-
signaling pathway in cells that only express gp130. Thus, it remains plausible that 
individuals with the 385Ala variant may show decreased classical activation due to 
reduced mIL6R, which perfectly explains the decrease in acute phase proteins, but 
may display increased (not decreased) trans-signaling due to increased IL6 and 
sIL6R levels. Another polymorphism in the human gp130 homologue, IL6 signal 
transducer was reported to be associated with CAD. However, the association was 
mostly limited to the ostium of the coronary arteries in very selected patient 
populations [85]. Thus, further studies are needed to elucidate the role of classical 
and trans-signaling of IL6 in the human setting. 
Clinical trials:  
Several antibodies were designed to inhibit the IL6 pathway and have been used in 
phase II and III clinical trials to study their efficacy in RA, and other autoimmune 
diseases and certain cancers. Tocilizumab is a monoclonal humanized antibody of 
the IgG1 class that was generated by grafting the complementarity determining 
regions of a mouse anti-human IL6R antibody onto human IgG1. It blocks IL6-
mediated signal transduction through inhibition of mIL6R and sIL6R. Its use to 
treat RA has been approved in more than 90 countries worldwide. Data regarding 
the safety of tocilizumab have been collected from RA patients and the overall 
safety profile is consistent across all global clinical studies. Patients with RA 
present increased risk of fatal CV accidents, but paradoxically they also present 
with lower cholesterol levels. Treatment with tocilizumab in RA patients has been 
associated with a significant improvement of the disease, but was associated with 
increased circulating levels of total cholesterol and triglycerides [86,87]. The 
results were corroborated in several trials. In the ADACTA (Adalimumab Acterma) 
phase IV clinical trial, monotherapy with tocilizumab was compared to 
adalimumab (anti-TNF monoclonal antibody) in MTX refractory RA patients. 
Tocilizumab treatment was associated with greater reduction in CRP and other 
anti-inflammatory composites compared to adalimumab, despite increasing 
circulating lipid levels [88]. Tocilizumab effect on lipid parameters is probably 
unrelated to direct blockade of IL6 signaling as it was not observed in individuals 
carrying the IL6R variant 358Ala [81,82]. It is also argued that while all 
lipoproteins are increased with tocilizumab, LDL/HDL, TC/HDL and ApoB/ApoA1 
ratios, which predict CV risk more accurately than other lipid parameters, remain 
the same, suggesting little direct impact of lipoprotein changes on CV risk. Several 
phase IV clinical trials have tried to provide insight into this paradoxical effect on 
lipids studying not only quantitative but also qualitative lipoproteins changes in 
RA patients treated with tocilizumab. As an example, treatment with tocilizumab 
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on top of MTX did not significantly increase pro-atherogenic small dense LDL, but 
significantly increased (non-atherogenic) small and medium HDL particles, in 
comparison to MTX alone. Paraoxonase 1 was increased, and HDL-associated 
serum amyloid A and sPLA2-IIa were decreased after tocilizumab, suggesting that 
IL6R blockade may promote an HDL translational change into a less inflammatory 
state [89]. However, circulating levels of HDL-cholesterol and sPLA2-IIa are only 
markers of CV risk and have both been invalidated as causal factors in human CAD 
(see below for sPLA2). In the double-blind phase of the five core studies of 
tocilizumab, a decreased number of MI were reported with all tocilizumab doses 
[90]. However, more evidence is needed regarding the impact of tocilizumab on CV 
events in patients with RA before starting trials to test the efficacy of tocilizumab 
in CV diseases outside the RA field. 
 
Lp-PLA2 
Pathophysiological pathway: Phospholipases A2 (PLA2) belongs to a superfamily 
of enzymes that hydrolyses glycerophospholipids at the position sn-2, producing 
non-esterified fatty acids (p.e. arachidonic acid and lysophospholipids).  PLA2 are 
classified as either cytosolic or extracellular, lipoprotein associated PLA2 (Lp-PLA2) 
and secreted PLA2 (sPLA2) belong to the latter group of enzymes.  
Lp-PLA2 is a Ca2+-independent 45kDA secreted protein that circulates in plasma 
associated with lipoproteins. In healthy individuals, it is typically associated to LDL 
and to a lesser extent to HDL and lipoprotein a (Lp-a) (extensively reviewed in 
[91]). It is widely secreted by immune cells involved in atherosclerosis such as 
macrophages, T lymphocytes and mast cells. It exhibits phospholipase and lipase 
activities. It was first discovered for its ability to hydrolyze platelet-activator factor 
factor (PAF) and so was called PAF-acetylhydrolase, but it also hydrolyzes oxPL. By 
cleaving an oxidized phosphatidylcholine component of the lipoprotein particle, it 
generates potent proinflammatory and proatherogenic mediators like oxidized 
non-esterified fatty acids, arachidonic acid and lysophosphatidylcholine (LysoPC). 
OxPLand fatty acids may promote atherosclerosis through a range of mechanisms 
(extensively reviewed in [91]). The effects of cyclooxygenases and lipoxygenases 
on arachidonic acid may generate proatherosclerotic mediators such as 
thromboxanes and leukotrienes. LysoPC increases endothelial activation, 
monocyte recruitment and differentiation into M1 pro-inflammatory macrophages. 
Experimental studies: Several studies found an atheroprotective role of Lp-PLA2 
in Apoe-/- mice and in a post-angioplasty restenosis model in rabbits [92,93]. 
Nevertheless, Lp-PLA2 is bound to HDL in mice, while it is attached to LDL in 
humans. Thus, murine experimental studies were not considered to be very 
informative. In hypercholesterolemic minipigs however, a correlation was found 
between oxLDL, lysoPC and Lp-PLA2 levels resulting in accelerated atherosclerosis 
[94]. On the other hand, diabetic/ hypercholesterolemic swines treated with 
darapladib (a selective pharmacological inhibitor of Lp-PLA2) presented a 
significant decrease of lysoPC in lesions, associated with significant, although 
modest, reduction of atherosclerotic plaque size and necrotic core area [95].  
Translational studies:  
Lp-PLA2 was demonstrated to be highly up- regulated in macrophages located in 
the lipid core and fibrous cap of vulnerable and ruptured human coronary arteries, 
but not within stable lesions [96]. The reason for this may be due to the fact that 
pro-inflammatory macrophages M1 (more abundant in the necrotic core of 
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unstable plaques) secrete much higher amounts of this enzyme than the anti-
inflammatory M2. Indeed, patients with a previous episode of CV event express 
higher Lp-PLA2 and lysoPC than patients with no CV history, suggesting a potential 
role of Lp-PLA2 in plaque composition and vulnerability. 
Several epidemiological studies (reviewed in [91]) tried to elucidate the potential 
prognostic value of Lp-PLA2 in CAD but reached opposite conclusions. A meta-
analysis evaluating data from 36 prospective studies with a total sample size of 
126,634 patients concluded to a modest association between Lp-PLA2 
concentration, but not activity, with CAD [97]. However, another meta-analysis 
analyzing data from 79,036 individuals in 32 prospective studies found a 
significant correlation between Lp-PLA2 mass or activity and CAD [98]. Several 
polymorphisms have been related to different levels of Lp-PLA2 activity. However, 
inconsistent results were reached regarding their association with CAD. A 
missense polymorphism Val279Phe in PLA2G7 gene is present in approximately 
30% of the Japanese population, and heterozygotes or homozygotes carriers of this 
polymorphism display reduced or no catalytic activity respectively; those 
individuals are not protected from CAD. A meta-analysis compiling information 
from 14 association studies focusing on 3 polymorphisms A379V, V279F and R92H, 
concluded to an association between R92H allele and increased CV risk, but that 
variant was not associated with significant changes of Lp-PLA2 activity. The other 
279F and 379V variants were associated with decreased Lp-PLA2 activity but were 
not associated with CHD risk [99]. Finally, in a recent study, carriers of loss-of-
function variant in PLA2G7 (rs140020965; Q287X) had almost 3-fold lower levels 
of Lp-PLA2 activity but no difference in risk of incident CAD compared with non-
carriers [100]. 
Clinical trials 
Darapladib was developed as a potent and reversible oral inhibitor of Lp-PLA2. 
Based on some epidemiologic studies supporting an association between Lp-PLA2 
and CV risk, several clinical trials were launched to assess the effect of darapladib 
on CV events in patients with stable or unstable CAD. After two encouraging phase 
II clinical trials [101,102], two phase III clinical trials were launched. In the 
STABILITY (Stabilization of Atherosclerosis Plaque by Darapladib Initiation of 
Therapy) trial, 15,828 patients with stable CAD were randomly assigned to 
darapladib 160 mg/day or placebo (on top of optimal treatment) for a total of 3.7 
years. Unfortunately, darapladib did not reduce the incidence of the primary 
endpoint, a composite of CV death, MI or stroke [103]. Some have argued that the 
negative result could be explained by the fact that those patients were already on 
statins, drugs with a very important impact on cholesterol levels (both groups 
presented LDL levels below 70 mg/dL) and Lp-PLA2 (it has been previously 
reported that statins reduce Lp-PLA2 levels by 35%). The second phase III clinical 
trial, SOLID-TIMI 52 (the Stabilization of Plaques Using Darapladib-Thrombolysis 
in MI 52 Trial) evaluated the effect of darapladib (160 mg/day) vs. placebo in 
13,026 patients with ACS for an average period of 2.5 years. Again darapladib 
treatment did not improve the primary endpoint of major CV events [104]. Overall, 
the use of darapladib is not recommended for the treatment or prevention of CV 
events. 
sPLA2 
Pathophysiological pathway: sPLA2 are a group of enzymes with low molecular 
weight (from 14 to 19 kDa) and a Ca2+-dependent phospholipase activity. Various 
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sPLA2 may exhibit independent non-redundant roles. They are localized in 
different chromosomes, though 6 of them reside in the same gene cluster. Among 
them, the sPLA2-II/V cluster has been described in humans to be a candidate 
susceptibility locus. Both, sPLA2-II and V are increased by proinflammatory stimuli 
and are downregulated by anti-inflammatory cytokines. sPLA2-II accumulates in 
inflammatory fluids (p.e. synovial fluid in patients with RA) and is constitutively 
expressed in organs dealing with inflammatory responses like spleen, thymus, 
bone marrow, intestines, ovary and lung [105]. sPLA2-V is constitutively expressed 
in different tissues but mainly in the heart .  
sPLA2-II, III, V and X are able to hydrolyse phosphatidylcholine in LDL leading to 
the formation of unsaturated fatty acids and lysoPC. They also give rise to the 
formation of smaller and denser LDL and enhance foam cell formation, potentially 
exhibiting an important role in the initiation of atherosclerosis. Because sPLA2-III, 
V and X are not detected in high concentrations in serum, they are believed to 
exert their actions on LDL accumulated in the intima. sPLA2-IIA is the predominant 
isoform in serum and the arterial wall, and despite having a modest LDL 
hydrolyzing activity, its high levels may somehow compensate for its low activity. 
sPLA2 also exhibit non-enzymatic roles, through binding to M-type receptors on 
neutrophils, monocytes and macrophages, inducing pro-inflammatory cytokines 
and chemokine production. 
Experimental evidence: C57Bl6 mice have a natural null mutation in the sPLA2-
IIA gene (Pla2g2a), thus several mouse lines overexpressing different human 
sPLA2 have been developed. Transgenic Pla2g2a C57Bl6 mice presented bigger 
atherosclerotic lesions than their WT littermates after the consumption of a high 
fat diet [106]. The same results were obtained in Ldlr-/- transplanted with BM from 
Pla2g2a Tg mice and macrophage-specific Pla2g2a Tg mice, thus confirming an 
atherogenic role of sPLA2-IIA in mice [107]. 
Transplantation of Ldlr-/- with BM from transgenic Pla2g5 gene promoted 
increased atherosclerotic plaques [108]; whereas mice transplanted with Pla2g5-/- 
BM had reduced atherosclerotic lesion size and collagen deposition in comparison 
to their WT littermates [108]. Nevertheless, Apoe-/- mice with deficiency in Pla2g5 
did not show decreased atherosclerotic plaques despite lower collagen deposition. 
These controversial results were attributed to differential enrichment of Apoe-/- 
(compared to Ldlr-/-)-derived LDL in sphingomyelin, which alters sPLA2-V 
hydrolytic activity. 
sPLA2-X shows the most potent hydrolyzing activity toward PC, suggesting a pro-
atherogenic role. However, Ldlr-/- transplanted with BM from mouse group X- 
deficient mice (Pla2g10-/-) surprisingly had bigger atherosclerotic plaques. Also, 
overexpression of human PLA2G10 in murine bone marrow cells led to significant 
reduction of Th1 response and atherosclerotic plaque development, challenging 
the pro-atherogenic paradigm of sPLA2 activity, and suggesting that inhibition of 
total sPLA2 activity may lead to detrimental CV effects [109]. 
Varespladib (from Anthera Pharmaceuticals) is a drug that specifically inhibits –
sPLA2-IIA, V and X but does not act on sPLA2-III. Its protective role on 
atherosclerosis has been tested in 2 different studies using Apoe-/- mice. 
Varespladib used alone significantly decreased atherosclerotic plaque formation 
and aneurysm development when compared to non-treated animals [110]. In the 
second study, varespladib was used in combination with a statin (pravastatin) at 
low doses; this combined effect decreased atherosclerosis to a bigger extent than 
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each drug on its own, supporting a potential synergistic effect between these two 
drugs [111]. 
Translational studies: Several epidemiological studies tried to address the 
potential prognostic value of sPLA2 in atherosclerosis. Elevated sPLA2-IIA levels 
have been associated with increased CV risk in several cohorts of patients with 
stable CAD [112–114]. The largest study that confirmed the prognosis value of 
sPLA2 in stable CAD patients was the PEACE study where elevated levels of sPLA2 
were significantly associated with the risk of CV disease, MI and stroke, even after 
multivariate adjustment including Lp-PLA2 and CRP [115]. Disappointingly 
however, Mendelian randomization studies did not support a causal role for sPLA2 
in CHD [116,117].  
Clinical trials: Several clinical trials have been launched to study the security and 
efficacy of varespladib in CAD. PLASMA I (phospholipase levels and serological 
markers of atherosclerosis) was a phase II, randomized, double-blind and placebo-
controlled, parallel-arm, dose-response clinical trial to evaluate the effect of 4 
different doses of varespladib in 396 patients with stable CAD [118]. The aim was 
to study the effect of an 8-week treatment on sPLA2-IIA levels, oxLDL, hsCRP, LDL 
particle size, plasmatic arachidonic acid and leukotriene B4 levels. The authors 
reported a dose-dependent decrease in sPLA2-II (reaching up to 90% in treated vs. 
5% in placebo) in patients treated with varespladib. Treatment also led to an 8% 
significant decrease of LDL levels in comparison to placebo. No significant changes 
were found in any other CV biomarker. PLASMA II was also a phase II, randomized, 
placebo-controlled study that was launched to study the effect of a daily single 
dose of varespladib (two different doses, 250 and 500 mg) in 197 patients with 
stable CAD, and reached the same conclusion as PLASMA I [119].  
Another phase II clinical trial called FRANCIS (Fewer Recurrent Acute coronary 
events with Near-term Cardiovascular Inflammation Suppression) was designed to 
examine the impact of 500mg of varespladib or placebo in association with 
atorvastatin 80 mg daily administered to patients within 96 hours of an ACS event 
and for 6 months. Varespladib treatment successfully reduced cholesterol, CRP and 
sPLA2-IIA levels [120]. These results led to a phase III clinical trial VISTA-16 that 
included more than 5,000 patients worldwide. Despite achieving lower cholesterol 
and CRP levels, patients treated with varespladib were not protected against the 
recurrence of CV events. The trial was stopped before completion due to increased 
incidence of MI in the varespladib group. Thus, varespladib may be harmful and is 
not a useful strategy to reduce adverse CV outcomes after ACS [121]. The results 
could have been predicted based on some experimental [109] and Mendelian 
randomization studies [116,117]. 
 
Therapies targeting the adaptive CD4+ T cell immune response 
 
The adaptive immune response is a specialized response. Innate immune cells, 
mainly macrophages and DC, act as antigen presenting cells (APC) and initiate the 
adaptive immune response. They drive the maturation and polarization of naïve 
CD4+ T cells through exposure of antigenic peptides on major histocompatibility 
complex class II molecule (MHCII), along with the engagement of co-stimulatory 
pathways. The antigenic epitopes that drive specific adaptive T cell immune 
responses in atherosclerosis are still to be characterized. However, an increasing 
body of evidence suggests a potential role for oxidized or native ApoB100-derived 
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epitopes, but antigens derived from heat shock protein 60/65 or other proteins 
may also play a role [122,123]. Activated T cells will differentiate into specific Th 
subtypes that secrete specific sets of cytokines and provide help to B cells favoring 
isotype switching, antigen-specific antibody production and induction of antibody-
producing plasma cells. The role of B cells in atherosclerosis has previously been 
published in this journal [124]. Therefore, we will focus here on the role of T cells. 
Primed naïve T cells can differentiate into at least 4 major T cell subtypes: Th1, 
Th2, Th17 and T regulatory (Tregs) cells. Polarization is induced by DC presenting 
antigens through MHCII to the TCR and interaction with co-stimulatory molecules 
like CD80, CD86, CD40 and OX40, binding to CD28, CD40L and OX40L on T cells. 
Additional soluble or membrane bound factors contribute to T cell polarization, 
e.g., IL12 and IL18 favor Th1 differentiation, CCL2, IL13 and IL6 may drive Th2, 
and TGF, IL6 and IL1 promote Th17. Treg polarization requires MHCII-TCR 
binding along with low level co-stimulation through CD80/CD86 with CD28, 
CD80/CD86-CTLA4 and/or ICOS-ICOSL.  All types of Th and Treg cells have been 
found in human atherosclerotic plaques, Th1 being the most prevalent. In general 
Th1 and its signature cytokine IFN play an atherogenic role and their detrimental 
role in atherosclerosis has been extensively reviewed previously. Unfortunately, 
therapeutic tools that specifically target the Th1 response are not currently 
available. We will therefore focus on the other T cell subtypes. 
 
Th17:  
Pathophysiological pathway: Specific polarizing cytokines are required for Th17 
differentiation. In mice, TGF represses Th1 and Th2 transcription factors, 
allowing IL6 to induce Th17 differentiation. IL6 activates STAT3 to up-regulate 
retinoic acid orphan receptors (ROR)  and t, leading to the induction of the Th17 
program. Also, in the absence of TGF, IL6 and IL23 in conjunction with IL1 may 
cooperate to induce IL17 secretion and induce Th17 polarization (extensively 
reviewed in [125]). Upon activation, Th17 cells produce signature cytokines IL17, 
IL21 and IL22. However, Th17 do not represent a homogeneous subset, and can be 
reprogrammed into other T cell subsets depending on the cytokine environment. 
In fact, IL17 can be co-expressed with other cytokines like IFN, IL10 and IL4. Th17 
may exhibit plasticity between Th1 cells and Tregs: a Th1/Th17 subset that co-
expresses Tbet and RORt has been found in some autoimmune settings, and a 
subset of RORt+ T cells that co-expresses Foxp3+ has also been identified. These 
recent findings involving Th17 plasticity may account for their controversial role 
in atherosclerosis. 
The IL17 family includes 6 members, IL17A (known as IL17) to IL17F (known as 
IL25), that all bind to IL17 receptor (IL17R), which consists of 5 subunits (IL17RA-
IL17F). IL17RA is ubiquitously expressed throughout the body, resulting in a wide 
range of pleiotropic actions of IL17. IL17 enhances several pro-inflammatory 
signaling pathways including NF-B and MAPK, which activate downstream target 
genes with important implications in atherosclerosis, mainly CXCL1 and 2 
(involved in neutrophils and monocyte chemoattraction), IL6, IL1, MMPs and 
granulocyte MCSF.  
Experimental evidence: The role of Th17 has widely been studied in mouse 
models of atherosclerosis, and has been shown to exert both pro and anti-
atherogenic effects (extensively reviewed in [125]). This is true for models using 
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Il17a-/- mice, IL17A blocking antibodies, IL17A recombinant protein, or any other 
methodology used to down- or up-regulate IL17A signaling [126–133]. 
A recent experiment that had not been discussed in the previous review on the 
role of IL17 signaling in atherosclerosis[125], reported significant reduction of 
atherosclerotic plaque formation and increased stabilization after administration 
of a mouse anti-mouse IL17A antibody to 32 weeks-old Apoe-/- mice fed a control 
chow diet [134]. However, we believe that the validity of this new study is 
compromised by the fact that the reported lipid profile (equivalent levels of total 
cholesterol and LDL-C at around 200 mg/dl) did not correspond to an Apoe-/- 
mouse. Thus, our current interpretation of the bulk of experimental studies on the 
role of IL17 signaling in atherosclerosis is the following: Atherosclerotic mouse 
models are mostly driven by a Th1 response; if both Th1 and Th17 are increased, 
the outcome will be increased atherosclerosis; however, if IL17 induction leads to 
limitation of Th1 responses, the outcome will most likely be a protection against 
exacerbated atherosclerosis. 
Translational studies:  
Robust evidence shows that IL17 mediates adverse effects in RA, multiple 
sclerosis, systemic lupus erythematosus, and psoriasis [135] but less is known 
about its potential role in atherosclerosis. Increased numbers of T cells expressing 
IL17 were found in atherosclerotic plaques [134]. Recombinant IL17 increased 
monocyte cell adhesion to EC in vitro, promoted macrophage polarization into a 
pro-inflammatory phenotype, and increased MMP9 secretion by ex vivo plaque 
cultures On the other hand, work from our lab suggested an atheroprotective role 
for IL17. IL17 was expressed not only by T cells, but also in normal SMC from 
healthy human arteries. Intriguingly, IL17 expression was significantly decreased 
in medial SMC underlying atherosclerotic plaques, although its expression was still 
detected in plaque T cells. Recombinant IL17 reduced EC activation (VCAM1 
expression) in culture, and high IL17 levels in human plaques were associated with 
a decrease in macrophage content and an increase of SMC and generally, with a 
more stable plaque [131]. Other investigators have subsequently corroborated the 
latter findings [136].  
A very few epidemiological studies addressed the association between Th17 levels 
in blood and CV risk. One study found a significant increase of blood Th17 cells in 
subjects with ACS (n=43) in comparison to patients with stable CAD or healthy 
controls (n=20) [137]. In another study, increased blood levels of Th1-Th17 cells 
were found in patients with ACS [138]. The same authors reported that Th1-Th17 
cultured cells from atherosclerotic coronary arteries produced a unique 
combination of IL17A and IFN after polyclonal stimulation compared with T cells 
from healthy vessels, inducing pro-inflammatory responses in vascular SMC [139]. 
However, we have shown that circulating IL17A substantially reduces human 
mononuclear cell adhesion to TNFα-activated human umbilical vein EC, which 
was associated with a significant reduction of sVCAM-1 expression, despite an 
increase of IL6 [140]. Moreover, in a large prospective and multicentric study 
enrolling 981 patients after an acute MI, low levels of circulating IL17 were 
associated with increased (not decreased) risk of all-cause death and recurrent MI 
at 2 years. IL17 was also negatively correlated with sVCAM1 levels, suggesting an 
important role of IL17 in EC activation. Thus, further translational studies must be 
performed before any definitive conclusion can be reached about the potential 
effect of Th17 T cell subtypes in atherosclerosis. 
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Clinical trials:  
Several neutralizing agents that inhibit IL17 signaling pathway have been 
developed due to their potential benefit in the treatment of autoimmune diseases. 
The first developed neutralizing antibody was ustekinumab, which targets the p40 
subunit of the cytokines IL12 and IL23, and was approved in 2009 by the FDA to 
treat psoriasis. The biggest phase III Clinical Trial ACCEPT that demonstrated the 
efficacy of ustekinumab in psoriasis has already been reviewed in detail in this 
Journal [141].  
Subsequently, at least two other IL17 neutralizing antibodies (secukinumab and 
ixekizumab) and one receptor blocking antibody (brodalumab) were developed 
and shown to be successful in Phase II Clinical Trials targeting autoimmune 
diseases like psoriasis. In fact, last year based on the results obtained in the CLEAR 
Phase III trial comparing ustekinumab and secukinumab, the latter was announced 
to be the first line-systemic treatment for moderate to severe plaque psoriasis. It is 
very intriguing however to note that in the placebo-controlled trials conducted to 
date, major CV events occurred only in the active arm, not in the placebo-treated 
group. As an example, in a recent study that addressed the effect of intravenous 
secukinumab (at a dose of 10 mg per kilogram) at weeks 0, 2, and 4, followed by 
s.c. secukinumab at a dose of either 150 mg or 75 mg every 4 weeks, or placebo for 
a maximum of 24 weeks, 4 strokes and 2 MI were reported in the secukinumab 
group [142], and none in the placebo group [143]. During the placebo-controlled 
phases of the anti-p40 studies, 10 of 3179 patients receiving anti-p40 therapies 
experienced major adverse cardiovascular events compared with zero events in 
1474 patients receiving placebo. By comparison, in the anti-TNF trials, only 1 of 
3858 patients receiving anti-TNF therapy experienced a MACE compared with 1 of 
1812 patients receiving placebo [143]. Thus, further experiments are needed to 
evaluate the cardiovascular safety of anti-p40 or IL17A/IL17R blockade in the long 
term. In the meanwhile, we recommend that patients treated with inhibitors of 
IL17A pathway are regularly checked and monitored to avoid unexpected CV 
events. 
 
Tregs:  
Pathophysiological pathway: Tregs are negative regulators of immune effector 
cells and are required to maintain immune homeostasis. They are essential in 
mediating peripheral tolerance, preventing autoimmune diseases, and suppressing 
inflammatory responses. There are two major classes of CD4+CD25hi Tregs, 
naturally occurring Tregs (nTregs) and adaptive/induced Treg cells (iTreg) 
(reviewed in [144]). They depend on IL2 for development and survival. nTreg 
comprise a 5-10% of the total CD4+ T cells in mice and humans, they mature within 
the thymus and they express Foxp3. Several important functions related to 
autoimmunity and atherosclerosis have been associated with Tregs. Fully mature 
nTreg cells exit the thymus, and migrate to secondary lymphoid organs (i.e. lymph 
nodes, spleen) [145]. Tregs also migrate to atherosclerotic arteries [146] and 
accumulate in tertiary lymphoid organs located in the adventitia of highly inflamed 
atherosclerotic vessels [147].  Tregs suppress autoimmune T cell proliferation and 
polarization, and inhibit polyclonal T cell activation, as well as the function of B 
cells, macrophages and DC. The mechanisms behind this immune suppressive role 
are multiple and may involve cell-to-cell contact, membrane-bound TGF, IL10, 
CTLA4 or T effector cell deprivation of IL2. 
 20 
On the other hand, iTreg cells mature in the periphery from a CD4+CD25- T cell 
population. Upon stimulation within a favorable microenvironment (in the 
presence of TGF, IL10 or IL4, but in the absence of IFN, IL1, IL6 or IL12) they 
may become CD4+CD25+ T cells with regulatory properties and a more or less 
stable Foxp3 expression. In the atherosclerosis setting they suppress T cell 
proliferation and activation, inhibit foam cell formation and redirect macrophage 
differentiation into the anti-inflammatory M2 phenotype.  
Experimental evidence: Apoe-/- mice have less Tregs in the spleen and 
demonstrate impaired immune suppressive properties compared to age-matched 
WT mice. In Ldlr-/- mice, splenic Treg numbers increase after 4, 8 and 20 weeks on 
high fat diet. However, the numbers of circulating and lesional Treg peak at 4 
weeks and decrease significantly at 8 and 20 weeks, concomitant with increased 
numbers of CD4+ effector T cells and increased lesion size over that period [146]. 
There is extensive evidence in mice implicating an anti-atheroslcerotic role for 
Treg cells. Significant aggravation of atherosclerosis is observed in different mouse 
models with depleted Tregs [144,148,149]. These include Treg deficiency due to 
deletion of CD80/CD86, CD28, ICOS, Foxp3-expressing T cells or Treg deficiency 
induced by the absence/depletion of tolerogenic DC or by injection of anti-CD25 
blocking antibody. Also, depletion of Treg signature cytokines IL10 and TGF leads 
to exacerbated atherosclerosis, further supporting an atheroprotective role for 
Tregs.  
On the other hand, adoptive transfer of CD4+CD25+ or Tr1 cells, as well as 
expansion of Tregs after blockade of CCL17, significantly reduced atherosclerotic 
lesion development in Apoe-/- [150]. Strategies for vaccination or tolerization to 
enhance (antigen-specific) Tregs in atherosclerosis have been developed in mice, 
with mixed results [151–157]. This is mostly due to our limited knowledge about 
the causal antigenic epitopes in atherosclerosis [158] and the subtype of DC to be 
targeted in order to selectively induce a Treg response [159–164].  
Administration of IL2/anti-IL2 mAb complexes, which leads to sustained increase 
of IL2 levels and a 10-fold increase of Tregs levels in blood, resulted in a significant 
reduction of atherosclerotic plaque formation and progression in Ldlr-/- mice 
[165]. Another experiment was designed to deliver IL2 directly into the 
atherosclerotic plaque. IL2 was coupled to L19, an antibody that recognizes the 
extradomain B of the extracellular matrix glycoprotein fibronectin (ED-B), which is 
differentially expressed in atherosclerotic plaques. Local IL2 administration 
significantly decreased the progression of pre-established atherosclerotic plaques 
due to the activation and proliferation of intra-plaque Treg cells in Apoe-/- mice 
[166]. 
Translational studies: Treg are detected in much lower amounts in 
atherosclerotic plaques (1-5% of all T cells) than in any other inflamed tissue (25% 
of all T cells in eczema and psoriasis). This suggests that local T cell imbalance in 
the atherosclerotic plaque may play an important role in disease progression. The 
mechanisms behind Treg reduction in atherosclerotic tissues are poorly 
understood (reviewed in [144]). A small study performed in 32 patients with ACS 
found reduced blood levels and less activated Tregs in comparison to healthy 
subjects [167]. A series of small size epidemiological studies corroborated those 
results [137,168,169]. In a random sample from the prospective Malmö Diet and 
Cancer Study (n=700 participants between 68-73 years old), the number of 
circulating Tregs was inversely correlated with the development of MI and 
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coronary events at follow-up [170]. Treg levels have also been inversely associated 
with plaque instability [171].  
Clinical trials: Adoptive Treg transfer limits the progression of CV diseases in 
mice, and has therefore been considered as a potential therapeutic strategy in 
humans though its development is being slow (extensively reviewed in [172]). Ex 
vivo expanded human Treg cells were effective in the prevention and treatment of 
graft-versus-host disease or type I diabetes mellitus [173,174]. But no data are 
available at present on the effects and safety of transferred Treg cells in patients 
with CV disease. Another strategy that could be applied to atherosclerosis would 
involve the isolation of autologous DCs, their subsequent loading with appropriate 
antigen(s) ex vivo (e.g., immunogenic epitopes of modified LDL), and their re-
injection to the patient. However, an important challenge is to select the right 
antigens and to target the right DC subset (reviewed in [175]).  
As explained above, IL2 is a major cytokine required for Treg generation and 
maintenance. Recombinant IL2 (aldesleukin) is currently available and approved 
for the treatment of renal cell carcinoma and metastatic melanoma. In those 
settings, IL2 treatment is not aimed at activation of Tregs but IL2 is administered 
at very high doses to activate anti-tumor T effector cell activity. Such high dose IL2 
may be associated with severe CV adverse effects (e.g., vascular leak syndrome 
characterized by tachycardia, increased vascular permeability and hypotension) 
due increased T cell activation and the occurrence of a “cytokine storm”. We 
propose to re-purpose aldesleukin for the treatment of CV diseases. Indeed, the 
effect of IL2 on Tregs is mediated by high-affinity IL2 receptors on Tregs. Beyond 
differences in receptor expression, Tregs also display exquisite sensitivity to IL2 
signaling compared to T effector cells. This makes (ultra)-low dose IL2 (which will 
selectively activate Tregs) an interesting and potentially useful tool to readjust the 
homeostatic imbalance between Tregs and T effectors in cardiovascular diseases. 
In Phase II clinical trials, low-dose IL2 has been demonstrated to be safe and 
efficient in the treatment of several auto-immune mediated diseases, including 
hepatitis C virus-induced vasculitis or graft-versus-host disease, increasing Treg 
levels by at least 2 fold, without any detectable activation of effector T cells 
[176,177]. We are currently testing a similar approach to promote Tregs in 
coronary patients with the aim to reduce vascular inflammation and limit 
cardiovascular events. 
 
Th2:  
Pathophysiological pathway: IL4 is the key cytokine that drives Th2 
differentiation. DC secreting IL6 or activated by TSLP to express OX40L promote 
CD4 naïve T cells polarization and differentiation into Th2. This leads to STAT6 up-
regulation and induction of GATA3, which activates the expression of signature 
cytokines IL4 and IL5, leading to inhibition of IFN production (reviewed in [178]). 
Like other Th subsets, Th2 also exhibit plasticity. For example, TGF induces Th2 
secretion of IL9 suggesting their conversion into Th9 cells. Due to their inhibition 
of Th1 polarization, an anticipated anti-atherosclerotic role was first hypothesized 
for Th2. However, recent data indicate that their role in atherosclerosis may 
depend on their cytokine profile. 
Experimental evidence: The first observation that suggested an athero-
protective role for Th2 cells came from an experiment performed in Th2-biased 
BALB/c mice, which were found to be resistant to atherosclerosis in comparison to 
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Th1-biased and athero-susceptible C57Bl/6 mice [179]. Moreover BALB/c Stat6-/- 
mice showed increased atherosclerotic plaque formation when compared to their 
WT littermates [180].  
Nevertheless, studies targeting Il4 led to controversial results. A first publication 
showed decreased atherosclerotic plaque formation in Ldlr-/- transplanted with 
BM from Il4-/- mice compared to WT [181]. But two subsequent experiments did 
not corroborate the results using either Apoe-/-/Il4-/- or Ldlr-/-/Il4-/- dKO mice 
[182,183]. More recent data suggest that selective targeting of type I IL4 receptor 
(IL4R and common  chain) may attenuate atherosclerosis in comparison with 
the targeting of the type 2 receptor (IL4R and IL13R1) [184]. Currently, two 
Th2-related cytokines have been shown to exert anti-atherosclerotic functions. IL5 
induces athero-protective antibody secretion in natural B1 cells. Transplantation 
of Il5-/- BM in Ldlr-/- enhanced atherosclerotic plaque formation, accompanied by a 
decrease in natural IgM production from B1 cells. The same authors also 
demonstrated that immunization of Apoe-/- mice with MDA-modified LDL reduced 
atherosclerosis through up-regulation of IL5 secretion and a resultant increase in 
natural IgM antibodies against oxidized epitopes [185]. IL33-dependent 
atheroprotection has also been attributed to Th2-mediated IL5 production and 
stimulation of B1-dependent natural IgM production [186]. 
IL13 is another Th2 secreted anti-atherogenic cytokine. Administration of IL13 to 
Ldlr-/- led to a significant decrease in atherosclerotic plaque formation and 
increased stability, in part through reduction of endothelial inflammation and an 
induction of a favorable alternative macrophage phenotype [187]. It is important 
to highlight though, that IL5 and IL13 are not specific to Th2 cells, and are also 
secreted by innate lymphoid cells 2 (ILC2), which may play significant roles in 
atherosclerosis. 
Translational studies: Immunologically, a skewed Th1/Th2 balance due to 
enhancement of Th1 cells and suppression of Th2 has been associated with the 
pathogenesis of human atherosclerosis [123]. The protective role assigned to Th2 
was initially related to the secretion of IL10, an anti-inflammatory cytokine with 
major protective role in atherosclerosis [188,189].  
IL4, however, has not been associated with protection from atherosclerosis in 
humans [190]. Recent epidemiological studies found higher levels of IL4 in plasma 
of subjects with CAD in comparison to healthy controls [191,192]. Interestingly, an 
association between CAD and variants near the IL5 gene locus was identified, 
suggesting a potential role of a Th2-related cytokine in the progression and 
development of CAD [193]. In this case, a putative atheroprotective effect has been 
initially suggested for IL5 due to the negative correlation between its plasma levels 
and carotid intima thickness [194]. A larger European prospective study concluded 
to a weak association between IL5 levels and CV risk in women, and no association 
in men [195]. Moreover, recent Mendelian randomization approaches could not 
support a role for IL5 levels in intima-media thickness [196], and suggested 
alternative mechanisms to explain the relationship between SNPs in IL5 gene locus 
and CV risk. Nevertheless, autoantibodies against IL5 were significantly associated 
with peripheral artery disease in a high-throughput screening of pooled serum 
[197].  
Clinical trials: Neutralizing antibodies against IL5 have been developed to treat 
severe asthma (reviewed in [198]). Given the potential atheroprotective role of 
IL5, we believe that we should be cautious about possible detrimental 
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cardiovascular effects that such anti-IL5 therapies may induce in patients with 
severe asthma, particular in patients at high baseline CV risk. Finally, it is 
interesting to note that low-dose IL2 therapy, which expands Tregs, has also been 
shown to promote IL5 production by ILC2 [199]. Those data favorably argue for 
the use of such a strategy (increasing Tregs and ILC2-derived IL5) to treat CV 
diseases. 
 
Conclusion 
It is might be disappointing to see that despite the large body of observational and 
mechanistic evidence that implicates immune responses in the development and 
complications of cardiovascular diseases, this knowledge has not been translated 
yet into benefit for the patient. There are several potential explanations and as 
discussed in the review, the failure of some trials could have been predicted on the 
basis of genetic Mendelian randomization studies. Another point to consider is that 
the various components of the immune system often play complex roles at 
different stages of disease development and progression and in different disease 
contexts, which may lead to different impact on disease outcomes. This is 
notwithstanding that the same cytokine or signaling pathway may differentially 
alter the disease process through induction of pro- or anti-inflammatory programs 
in different cell subtypes. Thus, the overall impact of cytokine signaling blockade 
on disease outcome is expected to be modest in the general population of patients 
with cardiovascular diseases. However, we believe that the therapeutic effect may 
be improved if we are able to stratify patients and assign selective therapies to 
appropriate patient populations, moving towards more personalized medicine. 
 
Expert commentary: There is extensive evidence relating the activation of the 
immune system to the development and complications of atherosclerosis, and 
recent data in humans support a causal role for some immune-mediated pathways 
in disease development. Yet, we still do not know whether manipulation of the 
immune system will have direct impact on disease outcome. Here, we have 
reviewed and discussed the most relevant innate and adaptive immune pathways 
currently considered for targeting in this setting, at the exception of B cell-
dependent responses, which have recently been reviewed in detail in the Journal  
[124]. We highlighted the extraordinary opportunity now offered to directly test 
the inflammatory hypothesis of atherosclerosis in the clinic using currently 
available therapeutics. However there are a few important points to keep in mind: 
1. The role of a given immune-mediated pathway in atherosclerosis is often 
interpreted in a simplistic dichotomic way, and important subtleties are frequently 
dismissed. For example, IL1 and IL1 signaling pathways are pro-atherogenic. 
However, little importance is attached to the potential undesirable effect of IL1 
blockade on lipid metabolism or plaque remodeling. IL6 pathway is almost 
invariably considered as pro-atherogenic despite the fact that deficiency of Il6 may 
be associated with acceleration of atherosclerosis. A similar comment pertains to 
the IL17A pathway, both in mice and in humans. Thus, a more balanced 
interpretation of the experimental and translational data is needed, which may 
help address and identify in more details the appropriate settings where an 
immune pathway can be targeted with minimal risk. 
2. Most experimental studies focus on the development of atherosclerosis. 
Intriguingly, it appears that a modulation of the inflammatory response is also 
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critical to the regression of atherosclerotic lesions (reviewed in [200]). Thus, 
increased attention should be directed to the understanding of the mechanisms of 
progression versus regression of established atherosclerotic plaques, with the aim 
to identify selective modulators of atherosclerosis regression.  
3. Negative results of some large phase III clinical trials could have been 
predicted by the results of some experimental or human genetic studies. This is for 
example the case for sPLA2 and Lp-PLA2 inhibitors where Mendelian 
randomization studies in humans were unable to detect any evidence of causal 
relationship between sPLA2 or Lp-PLA2 enzymes and cardiovascular diseases. Use 
of such genetic studies should be considered whenever possible before embarking 
on large phase III clinical trials. 
4. However, GWAS data addressing the causal relationship between immune-
mediated pathways and cardiovascular diseases should be interpreted with more 
caution. For example, the presence of an IL6R SNP, which is associated with higher 
circulating levels of sIL6R and IL6 but lower expression of mIL6R, has been 
interpreted as leading to increased IL6 signaling in a GWAS study that reported on 
the association between genetic variants and the risk for asthma [83,84], but was 
considered as responsible for reduced IL6 signaling in other GWAS studies that 
reported on the association between IL6R genotype and coronary heart disease 
[81,82] or abdominal aortic aneurysm [83]. This testifies to our ignorance of the 
true impact of that SNP on IL6 signaling, and to the urgent need for more studies to 
better understand the determinants and roles of classic versus trans IL6 signaling 
in disease development and complications. 
 
Five Year View:  
The next five years will certainly profoundly shape our understanding of the role 
of immune pathways in cardiovascular diseases, particularly in the clinical setting. 
Results of several ongoing clinical trials will be published, namely CANTOS and 
CIRT, and additional information will be available regarding the impact of IL6R 
blockade on cardiovascular risk. Several phase II and phase III trials will be 
initiated to further test the implication of selective immune pathways in CVD. For 
example, our lab will be testing low-dose IL2 therapy to limit vascular 
inflammation and coronary events in patients with acute coronary syndromes, and 
B cell depletion using CD20 mAb to reduce infarct size and improve left ventricular 
ejection fraction in patients with acute myocardial infarction. The discovery of new 
pathways involved in CVD will continue, and we expect interesting data to be 
available during the next 5 years on the mechanisms relating some genetic risk 
variants to CVD. Finally, identification of pro-atherogenic epitopes and a better 
understanding of antigen presentation and the role of selective dendritic cell 
subsets in modulating pro- and anti-atherogenic immunity will pave the way for 
specific manipulation of the immune system, through vaccination or tolerization, 
with the aim to achieve a cost-effective and sustained reduction in disease burden 
 
Key Issues:  
 
 Atherosclerosis is a chronic inflammatory disease where innate and 
adaptive immune responses play major roles at all stages of the disease. 
 Several phase III clinical trials are currently testing the immuno-
inflammatory hypothesis of atherosclerosis, the most promising ones being 
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CANTOS (anti-IL1) and CIRT (Methotrexate). However, failure of those 
trials should not detract from testing the validity of other immune-
mediated pathways to reduce CVD.  
 IL6R pathway is causally related to coronary artery disease and abdominal 
aortic aneurysm. However, more experiments are needed to clarify the 
specific contributions of each of the classical and trans-signaling pathways 
of IL6 to disease development and complications. 
 Studies are needed to evaluate the long-term cardiovascular safety of anti-
p40 and IL17A/IL17R blockade in patients with immune-mediated 
diseases. Meanwhile, we believe that those therapies should be avoided in 
patients at high cardiovascular risk. A similar cautious note applies to 
patients treated with anti-IL5 blocking antibodies.  
 Promoting Treg cells, either through administration of low-dose IL2 or 
antigen-specific activation, may hold promise in the treatment of patients 
with cardiovascular diseases.  
 
Figure 1: Currently available clinically approved drugs that interfere with 
the T cell response. Specific polarizing cytokines are required for naïve CD4+ 
T cells differentiation into various helper (Th1, Th2, Th17) and regulatory T 
cell (Treg) subsets. After stimulation Th cells secrete signature cytokines with 
different potential roles in atherosclerosis (protective or atherogenic). Several 
drugs have been developed to interfere with T helper and regulatory functions 
in clinical settings of immune-mediated diseases other than atherosclerosis. 
Some of these drugs are presented in the box in the bottom right corner of the 
Figure, and color-coded with their target molecule. The diagram shows that 
those available drugs may significantly impact atherosclerosis and 
cardiovascular risk either in a positive or a negative manner. 
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Table 1: Clinical trials targeting innate immune response 
Target Drug Clinical trial Disease  N Follow up Dose Result 
IL1 Anakinra MRC-ILA Study 
(Phase II) [35] 
Non-ST elevation ACS 
patients, with less than 
48h with chest pain 
182 1 year 10 mg daily 14 
consecutive days 
Reduce CRP first 
but then there is a 
rebound 
Increased CV 
accidents 
 Canakinumab Pilot Cantos [37] Diabetes Mellitus at 
high CV risk 
556 4 months 5, 15, 50 or 50 
mg/month 
Decreased hsCRP, 
Il6 and fibrinogen 
Slight increase 
triglycerides 
  Cantos (Phase 
III) [36] 
Post-MI with persistent 
elevations of CRP (>2 
mg/L) 
17,400 4 year 50, 150 or 300 mg 
or placebo every 3 
months  
Ongoing 
 Colchicine [40] ACS  40 24 h 1mg followed by 
0.5 mg 6-24 h 
before 
catheterization 
Decrease 
transcoronary IL1, 
IL18 and IL6 but not 
systemic levels 
  [39] ACS or acute 
ischaemic stroke 
80 30 days 1 mg/ day vs 
placebo 
Did not decrease 
CRP 
  LoDoCo (Phase 
III) [41] 
Stable CAD 532 3 years 0.5 mg/day or 
placebo for 3 years 
Positive with 
limitations (no 
blindo or placebo-
controlled) 
Unknown Methotrexate CIRT [59] Prior MI and either with, 
diabetes type 2 or 
metabolic syndrome 
7,000 3-5 years 15-20 mg/wk Ongoing 
Il6 Tocilizumab Meta-analysis 
(Il6 Consortium) 
[81,82] 
RA  139,449  4-8 mg/kg every 4 
weeks 
IL6R rs7529229 variant 
associated with 
reduced CRP and 
fibrinogen correlated 
with tacilizumab 
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  MEASURE 
(Phase IV) [89] 
In RA patients already 
treated with MTX 
132 8 mg/kg 1 year No effect on 
atherogenic small 
dense LDL 
Increased in non-
atherogenic LDL 
Increase PON1 
Decrease sPLA2 and 
amiloyd A 
  Five core Phase 
III [90] 
RA patients 4,199 
controls 
4,099 
patients 
8 mg/kg to 
4 mg/kg 
depending 
on side 
effects 
1-3 years Decrease MI 
 Adalimumab  
(ADA9 vs 
Tocilizumab 
(TCZ) 
ADACTA 
(Phase IV) [88] 
MTX refractory RA 
patients 
163 TCZ 
162 ADA 
8 mg/kg 
(TCZ) 
40 mg ADA 
6 years Decrease CRP 
Increase lipid levels 
Lp-PLA2 Darapladib Phase II [101] in coronary patients 
 
959 40, 80 or 
160 mg/day 
for 12 
weeks 
12 weeks Decrease Lp-PLA2 
Decrease Il6 and 
CRP 
  IBIS-2(Phase II) 
[102] 
angiographically proven 
CAD 
 
300 160 mg or 
placebo 12 
consecutive 
months 
12 months Decrease necrotic 
core expansion 
Decrease Lp-PLA2 
and no change in 
CRP 
  STABILITY 
[103] 
Stable CAD 15,828 160 mg/day 
or placebo  
 
3.7 years Failed in primary 
endpoints, did not 
decrease death due to 
MI, stroke or CV 
disease 
  SOLID-TIMI 52 
[104] 
ACS  13,026 160 mg/day 2.5 years Failed in any primary 
or secondary 
endpoint 
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sPLA2 Varespladib PLASMA I  
(Phase II) [118] 
Stable CAD 396  8 weeks Decrease sPLA2-II, 
oxLDL, hsCRP, LDL 
size 
Did not decrease 
LDLlevels 
  PLASMA II 
(Phase II) [119] 
Stable CAD 197 250 or 500 
mg daily 
8 weeks Same as PLASMA I 
  FRANCIS [120] 96 hours of an ACS 
event 
625 500mg 6 months Decrease colesterol, 
CRP and sPLAA2 
No effect in primary 
endpoint 
  VISTA-16 [121] 96 hours of an ACS 
event 
5,000 500 mg 6 months Increased MI rate 
 
 
 
 
 
 
